# Advances in SRNS Gene Research: From Precision Classification to Precision Diagnosis and Treatment

## TL;DR

This review explores how genetic research is transforming the diagnosis and treatment of steroid-resistant nephrotic syndrome (SRNS) through precision medicine.

## Contribution

The paper introduces a stepwise diagnostic system and highlights novel therapeutic strategies for SRNS based on genetic subtypes.

## Key findings

- SRNS is categorized into genetic (38–58%) and non-genetic/immune-mediated (40–60%) subtypes.
- COQ2/PDSS2 mutations respond to coenzyme Q10, while NPHS1 mutations require early renal transplantation.
- AAV-mediated gene therapy and CRISPR-Cas editing show preclinical promise but face clinical translation challenges.

## Abstract

To clarify the genetic classification, diagnostic strategies, and precision treatment pathways of steroid-resistant nephrotic syndrome (SRNS), this review systematically reviews the genetic stratification system of SRNS by integrating recent advances in genetic testing technologies and pathogenesis research. It contains the pathogenic mechanisms, diagnostic protocols, and therapeutic correlations of different genetic subtypes, while summarizing current progress and clinical challenges in gene therapy. Results indicate SRNS can be categorized into genetic (38–58%) and non-genetic/immune-mediated (40–60%). A stepwise diagnostic system comprising core proteinuria gene panel testing, whole-genome sequencing (WGS), whole-exome sequencing (WES), and supplementary multi-omics/long-range sequencing is proposed, suited for populations with “typical phenotypes and moderate genetic risk”, “atypical phenotypes and high genetic suspicion”, and “complex structural/non-coding region variants” respectively. Pathogenic mechanisms directly determine therapeutic strategies: COQ2/PDSS2 mutations respond to coenzyme Q10 suplementation, while NPHS1 mutations necessitate early renal transplantation. Adeno-associated virus (AAV)-mediated gene therapy and CRISPR-Cas editing show preclinical promise but face challenges including incomplete detection coverage and clinical translation difficulties. Genetic technologies are driving SRNS management transformation from “empirical treatment” to “mechanism-oriented precision diagnosis and therapy”. Future efforts should focus on overcoming genetic testing limitations and gene therapy translation bottlenecks to enhance diagnostic and therapeutic efficacy.